AbCellera Biologics Inc (NASDAQ:ABCL) currently has a daily average trading volume of 4.38M but it saw 2344342 shares traded in last market. With a market cap of 593.98M USD, the company’s current market price of $1.99 came falling about -4.78 while comparing to the previous closing price of $2.09. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.34 and as low as $1.89.
Taking a look at 20-day trading activity of AbCellera Biologics Inc (ABCL) gives us an average price of $2.22, while its current price level is -54.14% below from 52-week high level whereas it is 5.26% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.29 while that of 200 days or SMA-200 reads an average of $2.68. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.95% during that period while stretching the period over a month that increases to 6.22%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 36.99 which implies that the stock is in neutral territory.
The Benchmark Company upgraded its recommendation for the stock as a “Buy” from “Hold” on February 22, 2024 while assigning a price target of $9. KeyBanc Capital Markets issued its recommendations for the stock as it initiated the price target for the stock is $6.
Over the week, ABCL’s stock price is moving -2.93% down while it is -21.03% when we observe its performance for the past one month. Year-to-date it is -32.08% down and over the past year, the stock is showing a downside performance of -45.33%.
Currently, AbCellera Biologics Inc’s total number of outstanding shares is 298.36M with 22.97% of that held by the insiders while 46.23% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -15.45% and return on equity (ROE) at -15.59%. Stock’s beta reads 0.38. Stock has a price to book (P/B) ratio of 0.58 while price to sale or P/S ratio amounts to 25.69. Its return on asset (ROA) is -11.96% on average.
